Literature DB >> 31807571

Conversion therapy from N3 unresectable lung adenocarcinoma to radical surgery: a case report.

Huali Hu1, Shuai Zou1, Ruofu Xu1, Yoshinobu Ichiki2,3, Dirk De Ruysscher4, Fenglei Yu5, Aihui Liao1.   

Abstract

Patients with N3 non-small cell lung cancer (NSCLC) have unresectable tumors. Although significant progress has been made in the past decades for such tumors, the average median survival time remains at 10 months. Equally dismal long-term survival rates were reported with the average 5-year-suvival rate at 9%. Here, we report on a case of a patient with locally advanced disease that was treated with conversion therapy using targeted anti-PD-1 immunotherapy with platinum-based chemotherapy. Following this therapeutic regimen, the tumor showed a reversion to pN0 from pN3 and the patient showed a progression free survival time of at least 33 months. 2019 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Conversion treatment; N3 locally advanced NSCLC; immunotherapy neoadjuvant treatment

Year:  2019        PMID： 31807571      PMCID： PMC6861792          DOI： 10.21037/atm.2019.09.113

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


  5 in total

1.  Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Authors:  Corey J Langer; Shirish M Gadgeel; Hossein Borghaei; Vassiliki A Papadimitrakopoulou; Amita Patnaik; Steven F Powell; Ryan D Gentzler; Renato G Martins; James P Stevenson; Shadia I Jalal; Amit Panwalkar; James Chih-Hsin Yang; Matthew Gubens; Lecia V Sequist; Mark M Awad; Joseph Fiore; Yang Ge; Harry Raftopoulos; Leena Gandhi
Journal:  Lancet Oncol       Date:  2016-10-10       Impact factor: 41.316

2.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

4.  Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitors.

Authors:  Yoshinobu Ichiki; Akihiro Taira; Yasuhiro Chikaishi; Hiroki Matsumiya; Masataka Mori; Masatoshi Kanayama; Yusuke Nabe; Shinji Shinohara; Taiji Kuwata; Masaru Takenaka; Soichi Oka; Ayako Hirai; Naoko Imanishi; Kazue Yoneda; Koji Kuroda; Yoshihisa Fujino; Fumihiro Tanaka
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

Review 5.  The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer.

Authors:  Hisao Asamura; Kari Chansky; John Crowley; Peter Goldstraw; Valerie W Rusch; Johan F Vansteenkiste; Hirokazu Watanabe; Yi-Long Wu; Marcin Zielinski; David Ball; Ramon Rami-Porta
Journal:  J Thorac Oncol       Date:  2015-12       Impact factor: 15.609
  5 in total
  1 in total

1.  Conversion therapy from unresectable stage IIIC non-small-cell lung cancer to radical surgery via anti-PD-1 immunotherapy combined with chemotherapy and anti-angiogenesis: A case report and literature review.

Authors:  Guohua Jia; Shuimei Zhou; Tangpeng Xu; Yabing Huang; Xiangpan Li
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.